These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34559204)

  • 21. [Patient safety first. position paper of the German Rheumatism -- Ligazur introduction of biosimilars].
    Z Rheumatol; 2014 Sep; 73(7):676. PubMed ID: 25320752
    [No Abstract]   [Full Text] [Related]  

  • 22. Biosimilars, a new era in rheumatology in Spain.
    Díaz-González F; Bustabad-Reyes S
    Reumatol Clin (Engl Ed); 2020; 16(2 Pt 2):131-132. PubMed ID: 32063503
    [No Abstract]   [Full Text] [Related]  

  • 23. Biosimilars in rheumatology: perspective and concerns.
    Scheinberg MA; Azevedo VF
    Rheumatology (Oxford); 2014 Mar; 53(3):389-90. PubMed ID: 23878310
    [No Abstract]   [Full Text] [Related]  

  • 24. Biosimilars in Rheumatology- Name Changers or Game Changers?
    Handa R
    J Assoc Physicians India; 2017 May; 65(5 Suppl):6-8. PubMed ID: 28836744
    [No Abstract]   [Full Text] [Related]  

  • 25. Biosimilars in childhood chronic rheumatic diseases: friend or foe?
    Maccora I; Simonini G
    Lancet Rheumatol; 2024 Jul; 6(7):e413-e414. PubMed ID: 38843857
    [No Abstract]   [Full Text] [Related]  

  • 26. Update on biosimilars in rheumatology.
    Rischin A; Östör AJ
    Inflammopharmacology; 2017 Apr; 25(2):177-184. PubMed ID: 28265837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Era of biosimilars in rheumatology: reshaping the healthcare environment.
    Smolen JS; Goncalves J; Quinn M; Benedetti F; Lee JY
    RMD Open; 2019; 5(1):e000900. PubMed ID: 31245050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.
    Espinosa Morales R; Díaz Borjón A; Barile Fabris LA; Esquivel Valerio JA; Medrano Ramírez G; Arce Salinas CA; Barreira Mercado ER; Cardiel Ríos MH; Díaz Jouanen E; Flores Murrieta FJ; Fraga Mouret A; Garza Elizondo MA; Luján Estrada M; Muñoz Barradas FJ; Talavera Piña JO; Vera Lastra OL;
    Reumatol Clin; 2013; 9(2):113-6. PubMed ID: 23395225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
    Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Position paper of Italian rheumatologists on the use of biosimilar drugs.
    Atzeni F; Sebastiani M; Ricci C; Celano A; Gremese E; Iannone F; Meroni PL; Minghetti P; Sarzi-Puttini P; Ferraccioli G; Lapadula G
    Clin Exp Rheumatol; 2015; 33(1):1-4. PubMed ID: 25436597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comment on: The Portuguese Society of Rheumatology position paper on the use of biosimilars.
    Müller-Ladner U
    Acta Reumatol Port; 2014; 39(1):7-8. PubMed ID: 24811455
    [No Abstract]   [Full Text] [Related]  

  • 32. Rheumatology training and research in Iran.
    Khabbazi A; Soroosh M
    Rheumatol Int; 2019 Aug; 39(8):1307-1319. PubMed ID: 31111293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biosimilars: complements and comments on the recent statement of the SFR and CRI. Comment on: "Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI)." Schaeverbeke et al. Joint Bone Spine 2018;95:399-402.
    Cohen JD; Tropé S; Munos A; Bocquet F
    Joint Bone Spine; 2019 Mar; 86(2):287-288. PubMed ID: 30394338
    [No Abstract]   [Full Text] [Related]  

  • 34. Therapy: Biosimilars in rheumatology - why, how and when in 2017.
    Fleischmann R
    Nat Rev Rheumatol; 2017 Dec; 13(12):701-703. PubMed ID: 29097811
    [No Abstract]   [Full Text] [Related]  

  • 35. Use of Biologics and Biosimilars in Rheumatology.
    Sharma SK
    J Assoc Physicians India; 2017 May; 65(5 Suppl):9-14. PubMed ID: 28836745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biosimilars vs originators: Are they the same?
    Sarzi-Puttini P; Marotto D; Caporali R; Galeazzi M; Atzeni F; Hamar A; Soós B; Szekanecz Z
    Autoimmun Rev; 2019 Dec; 18(12):102404. PubMed ID: 31639517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars.
    Rezk MF; Pieper B
    Adv Ther; 2018 Jun; 35(6):749-753. PubMed ID: 29873005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology.
    Nikolov NP; Shapiro MA
    Nat Rev Rheumatol; 2017 Feb; 13(2):123-128. PubMed ID: 28053335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of biologic agents in rheumatology.
    Strand V; Goncalves J; Isaacs JD
    Nat Rev Rheumatol; 2021 Feb; 17(2):81-97. PubMed ID: 33318665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The changing landscape of biosimilars in rheumatology.
    Dörner T; Strand V; Cornes P; Gonçalves J; Gulácsi L; Kay J; Kvien TK; Smolen J; Tanaka Y; Burmester GR
    Ann Rheum Dis; 2016 Jun; 75(6):974-82. PubMed ID: 26964144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.